You're tuned in to Tech Beat, let's get into it.
Medicare is set to launch a weight loss drug benefit this July, giving enrollees access to GLP-one medications for a fifty dollar copay. It's a significant policy shift that could bring drugs like Ozempic and Wegovy within reach for millions of older Americans who've long been priced out of them.
And speaking of GLP-ones, the drugs are quietly reshaping retail in a way few anticipated. As more Americans lose appetite on these medications, they're returning clothing, food products, and portion-sized goods at rates that are straining retailers' return systems. It turns out changing how people eat also changes how they shop, and businesses are only beginning to reckon with that.
On a very different note, Anthropic co-founder Daniela Amodei is pushing back on skepticism about whether AI is actually delivering returns worth the enormous investment. With an IPO on the horizon, she's making the case that the technology is still early, that the payoff is real, and that the doubters are simply not looking at the right time horizon.
Keep surfing. Tech Beat out.
